Diagnostic criteria for constitutional mismatch repair deficiency (CMMRD): recommendations from the international consensus working group
- PMID: 33622763
- DOI: 10.1136/jmedgenet-2020-107627
Diagnostic criteria for constitutional mismatch repair deficiency (CMMRD): recommendations from the international consensus working group
Abstract
Background: Constitutional mismatch repair deficiency syndrome (CMMRD) is the most aggressive cancer predisposition syndrome associated with multiorgan cancers, often presenting in childhood. There is variability in age and presentation of cancers and benign manifestations mimicking neurofibromatosis type 1. Genetic testing may not be informative and is complicated by pseudogenes associated with the most commonly associated gene, PMS2. To date, no diagnostic criteria exist. Since surveillance and immune-based therapies are available, establishing a CMMRD diagnosis is key to improve survival.
Methods: In order to establish a robust diagnostic path, a multidisciplinary international working group, with representation from the two largest consortia (International Replication Repair Deficiency (IRRD) consortium and European Consortium Care for CMMRD (C4CMMRD)), was formed to establish diagnostic criteria based on expertise, literature review and consensus.
Results: The working group established seven diagnostic criteria for the diagnosis of CMMRD, including four definitive criteria (strong evidence) and three likely diagnostic criteria (moderate evidence). All criteria warrant CMMRD surveillance. The criteria incorporate germline mismatch repair results, ancillary tests and clinical manifestation to determine a diagnosis. Hallmark cancers for CMMRD were defined by the working group after extensive literature review and consultation with the IRRD and C4CMMRD consortia.
Conclusions: This position paper summarises the evidence and rationale to provide specific guidelines for CMMRD diagnosis, which necessitates appropriate surveillance and treatment.
Keywords: diagnosis; gastrointestinal diseases; genetics; heredity; medical; medical oncology.
© Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.
Conflict of interest statement
Competing interests: HH reports the following financial relationships: Scientific Advisory Board at Invitae Genetics, Medical Advisory Board at Promega, Scientific Advisory Board at Genome Medical, and consultant at 23andMe. None of the relationships presents a conflict of interest in this study. KJ is a full-time employee at Ambry Genetics. This does not present a conflict of interest in this study. LB reports grants from Fondation Gustave Roussy, during the conduct of the study. UT reports grants from SU2C Catalyst, grants from Meagan’s Walk, grants from IDRC - Joint Canada-Israel Health Program and grants from Canadian Institutes of Health, during the conduct of the study.
Publication types
MeSH terms
Substances
Supplementary concepts
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials